- Home
- MESO vs GNL Comparison
MESO vs GNL Comparison
Compare MESO & GNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- GNL
- Stock Information
- Founded
- MESO 2004
- GNL 2011
- Country
- MESO Australia
- GNL United States
- Employees
- MESO N/A
- GNL N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- GNL Real Estate Investment Trusts
- Sector
- MESO Health Care
- GNL Real Estate
- Exchange
- MESO Nasdaq
- GNL Nasdaq
- Market Cap
- MESO 1.4B
- GNL 1.6B
- IPO Year
- MESO N/A
- GNL N/A
- Fundamental
- Price
- MESO $10.97
- GNL $8.08
- Analyst Decision
- MESO Buy
- GNL Buy
- Analyst Count
- MESO 4
- GNL 4
- Target Price
- MESO $18.00
- GNL $9.50
- AVG Volume (30 Days)
- MESO 156.4K
- GNL 1.7M
- Earning Date
- MESO 02-26-2025
- GNL 05-07-2025
- Dividend Yield
- MESO N/A
- GNL 12.61%
- EPS Growth
- MESO N/A
- GNL N/A
- EPS
- MESO N/A
- GNL N/A
- Revenue
- MESO $5,670,000.00
- GNL $731,380,000.00
- Revenue This Year
- MESO $152.37
- GNL N/A
- Revenue Next Year
- MESO $336.12
- GNL N/A
- P/E Ratio
- MESO N/A
- GNL N/A
- Revenue Growth
- MESO N/A
- GNL 16.69
- 52 Week Low
- MESO $5.78
- GNL $6.51
- 52 Week High
- MESO $22.00
- GNL $9.11
- Technical
- Relative Strength Index (RSI)
- MESO 44.34
- GNL 67.86
- Support Level
- MESO $10.77
- GNL $7.35
- Resistance Level
- MESO $11.61
- GNL $7.64
- Average True Range (ATR)
- MESO 0.47
- GNL 0.17
- MACD
- MESO 0.09
- GNL 0.06
- Stochastic Oscillator
- MESO 27.68
- GNL 88.41
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.